LLY vs NYXH
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
NYXH exhibits severe financial distress as evidenced by a Piotroski F-Score of 1/9, indicating critical weakness across nearly all fundamental health dimensions. While the company shows explosive revenue growth (346.90% YoY) and maintains a strong gross margin of 63.13%, these are overshadowed by an unsustainable operating margin of -329.29% and a consistent track record of earnings misses. The stock is technically in a freefall with a 0/100 trend score and a 1-year price decline of 43.6%. Despite bullish analyst price targets, the deterministic data suggests a high-risk speculative profile with significant capital erosion.
Compare Another Pair
Related Comparisons
LLY vs NYXH: Head-to-Head Comparison
This page compares Eli Lilly and Company (LLY) and Nyxoah SA (NYXH) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.